HibernationThe Power of Hibernation
We use the protective mechanisms against cold, inactivity, starvation and asphyxiation to develop clinical applications for urgent, medical needs.
Sulfateq B.V. has developed a new class of chemicals (patent pending) and their applications, all in the field of cell preservation. In different animal models, these chemicals demonstrate their ability to be used for medical application. These applications are for a real medical need, servicing the blockbuster markets. All these chemicals emerged from the principles acquired in hibernation research.
In hibernation mammalian tissue and blood cells are protected against oxidative stress damage as the metabolism changes towards minimal need for oxygen and nutrition. It changes the metabolism and the tissue, the blood cells of hibernating animals can cool down to temperatures just above freezing point without cell damage or even loosing vitality.
Natural resistance against difficult circumstances
- Bears and other species use the protective mechanism of hibernation.
- Hibernation is nature’s solution for surviving harsh times.
- Surviving through a period of low food supply and cold temperatures.
TEDx talk about hibernation
On November 20th last year, Prof. Dr. R.H. Henning from the University of Groningen, the Netherlands, gave an interesting TEDx talk about hibernation and its importance for human medicine. TEDx Groningen just recently released the video of this inspiring talk ‘Is human hibernation possible?’
Sulfateq BV has a close working relationship with the University of Groningen, especially with Prof. Dr. R.H. Henning and his team, which led to the succesful development and synthesis of effective chemical compounds that can enhance protective processes for human cells and tissue; the so-called ‘SUL-compounds’.
1. Mammal survives by minimizing energy need.
2. Low oxygen consumption and body temperature
3. Long-term sufferings like hypothermia, starvation and disease susceptibility.
4. The animals have developed a suite of adaptations to protect mind and body.
5. No signs of severe damage to tissue or brain.
Development SUL-138 compound
As a result of a profound academic research of the phenomenon of hibernation of mammals in winter time Sulfateq has been able to use these great adaptations in nature for the benefit of medicine, known as biomimicry. In close collaboration with the University of Groningen chemical compounds such as SUL-138 have been identified and synthesised, Sulfateq has developed these compounds, which enable a phase of hibernation in human cells, cell lines and possibly in tissue as well. Other, similar compounds in the SUL series have properties, which enable organ preservation.
Sulfateq has brought this technology to a level where key aspects have been proven and the focused potentials must be further developed. Experiments done in several clinics and institutes already gave promising results for applications regarding organ preservation and drug development as well. We are currently in the development phase with the compounds. One compound has been used in the commercial available hypothermic preservation additive ROKEPIE®-FD01.
Thus far, SUL-138 has proven to increase mitochondrial respiration during stress, thereby allowing for faster recovery of ATP. This effect was observed in various cell culture models for oxidative stress and cooling-rewarming injury. Moreover, in an animal experiment employing a deep, whole body cooling in an anesthetized rat, the mixture of stereoisomer (the fully protect the kidney from cooling-rewarming induced organ damage). In this experiment, this mixture was administered via continuous intravenous infusion without any side-effects. As systemic biomarker for therapeutic efficacy of the SUL-138, the reduction in plasma ROS levels was used.
Using hibernation principles for preventing AKI
The main focus of SUL-138 is the prevention of Acute Kidney Injury (AKI) during cardiac surgery. The incidence of postoperative AKI of patients undergoing cardiac surgery is 15-30%, with 1.5 million occurrences a year worldwide. Hence, AKI can therefore be considered a major health risk and medical need. There is currently no prophylaxis available which protects the kidney from injury during major surgery, nor are these available for other organ injuries. With the development of SUL-138 AKI can be prevented, which results in a great reduction in patient morbidity and decrease in hospitalization costs. Moreover, SUL-138 also has multiple applications in other therapeutic areas.
Mechanism of action
Mitochondria in Health and Disease
Mitochondria are the cell’s source of energy and play an essential role in the proper functioning of cells and organs. Healthy mitochondria generate adenosine triphosphate (ATP), the energy molecule required by our cells and organs to function properly. Mitochondria also produce a minimal level of reactive oxygen species (ROS) as secondary products of respiration.
When mitochondria dysfunction, ATP production is reduced and ROS production is increased, with an accompanying increase in oxidative stress. The increased ROS that dysfunctional mitochondria produce can damage multiple cellular components (including DNA, proteins, lipids and the mitochondria themselves), which results in the disruption of normal biological functioning and disease.
Mitochondrial dysfunction is believed to arise either as a result of inherited genetic defects or through damage-signals encountered during disease. In either case, the result is the generation of excessive ROS and reduced ATP production. Dysfunctional mitochondria are a key element in a variety of serious diseases (both rare and common), and thus a promising therapeutic target.
The development of Mitochondrial Medicines is challenged by the difficulty of targeting the mitochondria (passing both the cellular membrane and the mitochondrial outer membrane) without affecting the mitochondrial membrane potential or causing mitochondrial toxicity.
SUL-138 appears to target and protect dysfunctional mitochondria without affecting healthy mitochondria and cells. SUL-138, in preclinical models, is a mitochondrial protective agent that improves cell viability and organ function in several disease models including renal, metabolic, pulmonological and hypothermia-associated disorders.
SUL-138 Mechanism of Action
SUL-138 is formulated for systemic intravenous infusion, but oral delivery formulations are currently under development with promising results.
In preclinical models, SUL-138 is uniquely able to reach the mitochondria, where it restores electron transport to improve cellular energy production and reduce oxidative stress created by the over-production of ROS.
SUL-138 functions via direct reduction of Cytochrome c and the maintenance of the enzyme Cytochrome c oxidase in the mitochondrial inner membrane. Extensive preclinical investigations have revealed that SUL-138, through its novel mechanism:
- Maintains mitochondrial bioenergetics under pathological conditions (including ultrastructure, membrane potential and respiration);
b. Increases ATP levels under pathological conditions; and
c. Decreases ROS production under pathological conditions.
These novel mechanisms ameliorates electron transport deficiencies in disease. Given these innovational mechanisms-of-action, SUL-138 can provide therapeutic benefits in mitochondrial disease, such as Acute Kidney Injury.
Mitochondria in Surgery-related Acute Kidney Injury
Acute kidney injury (AKI) is a critical clinical condition with no effective treatment. AKI incidence continues to increase and AKI is associated with high mortality at short and long-term, increased risk of progression to chronic kidney disease and end-stage renal disease. Cardiac bypass surgery is a common cause of AKI in humans with incidences as high as 30%. Survivors of AKI are plagued by a variety of chronic sequelae contributing to decreased quality of life and increased utilization of healthcare resources.
The initiation of AKI following cardiac bypass surgery is multifactorial and poorly understood, however ischemia-reperfusion (I/R) injury is pivotal. Hampered kidney perfusion – due to reduced cardiac output, increased systemic inflammation, hemodynamic alterations, volume depletion and perioperative administration of nephrotoxic drugs – contributes to I/R-induced AKI following cardiac surgery. Acute kidney injury (AKI) is defined by an acute rise in serum creatinine levels or decrease in urine output. As the bulk of renal cell mass is composed of tubular cells. Tubular cell death or injury is the main morphological feature of AKI. Tubular cells are extremely rich in mitochondria and mitochondrial abnormalities are a key feature of AKI.
This mitochondrial injury progresses into mitochondrial dysfunction, resulting in the inability to generate ATP and excessive ROS production (oxidative stress) and, thus, leading to cell injury. As a consequence mitochondria are therapeutic targets in the treatment of renal disease.
Mitochondrial dysfunction is a key pathophysiological element in AKI during both the initiation and recovery phases. Ischemia results in rapid tubular mitochondrial fragmentation and shortening. The mitochondrial membrane potential and mitochondrial respiration decrease while mitochondrial ROS increases. This results in ATP depletion, lipid peroxidation, and the release of proapoptotic proteins. Reperfusion, or kidney reoxygenation, results in rapid restoration of mitochondrial respiration and a burst in ROS production. However, the mitochondria remain impaired in their ATP synthesizing function. Thus, ATP recovery is often delayed, which inhibits the initiation of energy-dependent cellular repair mechanisms, and contributes to persistence of AKI.
SUL-138 maintains mitochondrial bioenergetics under pathological conditions such as ischemia/reperfusion and thus counteracts the processes that underlie the formation of AKI, i.e. tubular mitochondrial dysfunction. Maintenance of ATP generation under ischemic conditions and decreased ROS formation upon reperfusion protect the tubular cells from injury, whereas accelerated ATP formation would allow for repair of damage encountered during the ischemia-reperfusion phase.
Read The Most Recent Publications in the Field
A lot of research is being done in this field at the moment. That's why we make sure to keep you up to date!
Groningen, The Netherlands & Ankara, Turkey - Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a leading speciality pharmaceutical...
We are proud to announce that Sulfateq B.V. received a Samenwerkingsverband Noord-Nederland (SNN) Valorisation grant for the development of SUL-138 as Acute Kidney Injury (AKI) prophylaxis. This grant helps us to continue the development that was already stimulated by...
There is a new manuscript available which describes the positive effect of our SUL-109 compound which is commercially available as our ROKEPIE preservation solution. This article was written by Fatima Aerts from the Hacettepe University in Ankara (Turkey). You can...